Specialty Pharmacy

A large portion of patients who received experimental drug had their tumors stop growing.

Incretin-based drugs help type 2 diabetes patients reduce blood sugar.

Ability to produce epiregulin may influence cancer development.

Tops news of the day from across the healthcare landscape.

Skyrocketing prescription drug prices sit squarely at the center of policy debates about the US health care system.

Study evaluates whether smoking cigarettes worsens clinical damage in PsA patients as it does in rheumatoid arthritis and ankylosing spondylitis.

Raltegravir may help boost adherence and help prevent vaginal HIV transmission.

Patients with colorectal, breast, or prostate cancers taking low-dose aspirin along with chemotherapy are shown to have better survival rates.

Pathologists revised the terminology of a type of thyroid tumor to remove “cancer” from its name.

Radiation therapy plus chemotherapy extends overall survival in patients with grade 2 glioma.

Researchers seek to reverse lung injury caused by cancer treatments.

A commonly held axiom in specialty pharmacy is that the patient is at the center of every action.

In 2015, specialty medications accounted for 37.7% of total drug spending.

Obese people found to be at greater risk for developing colon cancer.

New initiative announced at Asembia (formerly Armada) Specialty Pharmacy Summit honors the work of caregivers who help patients battle debilitating diseases.

Increased amount of specific fatty acid underlies type 1 diabetes and obesity-related kidney dysfunction.

A new treatment for hepatitis B significantly reduced viral load in 4 weeks.

Infertility and breast density may impact the risk of cancer.

Combination treatment approach helps control diabetes and obesity.

Top news of the day from across the healthcare landscape.

When anti-microbial antibodies have accumulated for years before a person is diagnosed with Crohn’s disease, it is likely to increase complications.

Targeted approach may lead to improved treatments for cancer.

Prognostic model provides simple and accurate clinical description for each HCC patient.

JAK2 could potentially cause treatment resistance in TNBC.

New tool can detect chemical changes in DNA associated with liver fibrosis.

Bevespi Aerosphere is a twice-daily, fixed-dose dual bronchodilator combining a long-acting muscarcinic antagonist and a long-acting beta-2 agonist.

Top news of the day from across the health care landscape.

Pharmacist-led diabetes collaborative drug therapy management programs impact patients with type 2 diabetes.